Drugs that contain Brimonidine Tartrate
1. Alphagan P patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5424078 (Pediatric) | ABBVIE | Aqueous ophthalmic formulations and methods for preserving same |
Dec, 2012
(11 years ago) | |
| US10307368 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US9687443 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6562873 | ABBVIE | Compositions containing therapeutically active components having enhanced solubility |
Jul, 2021
(2 years ago) | |
| US9295641 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6627210 | ABBVIE | Compositions containing α-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6673337 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6641834 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
|
US9295641 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6562873 (Pediatric) | ABBVIE | Compositions containing therapeutically active components having enhanced solubility |
Jan, 2022
(2 years ago) | |
|
US9687443 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6627210 (Pediatric) | ABBVIE | Compositions containing α-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6673337 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6641834 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
| US8858961 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(7 months ago) | |
|
US8858961 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(a month ago) | |
Market Authorisation Date: 19 August, 2005
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
ALPHAGAN P family patents
2. Lumify patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596600 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(5 years from now) | |
| US11833245 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(5 years from now) | |
| US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(6 years from now) | |
| US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2020 |
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIFY family patents
3. Mirvaso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859551 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2024
(28 days from now) | |
| US8410102 | GALDERMA LABS LP | Methods and compositions for treating or preventing erythema |
May, 2025
(1 year, 27 days from now) | |
| US8426410 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2025
(1 year, 27 days from now) | |
| US8231885 | GALDERMA LABS LP | Compounds, formulations, and methods for ameliorating telangiectasis |
May, 2025
(1 year, 27 days from now) | |
| US7439241 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing rosacea |
Aug, 2025
(1 year, 3 months from now) | |
| US9861631 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US8513249 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US9861632 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US8513247 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US8163725 | GALDERMA LABS LP | Gel compositions and methods of use |
Jun, 2031
(7 years from now) | |
| US8053427 | GALDERMA LABS LP | Brimonidine gel composition |
Jun, 2031
(7 years from now) | |
| US10201517 | GALDERMA LABS LP | Brimonidine gel compositions and methods of use |
Jun, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2016 |
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL;TOPICAL
MIRVASO family patents
4. Qoliana patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7265117 | SANDOZ | Topical brimonidine tartrate formulations that lack chlorine dioxide |
Aug, 2025
(1 year, 3 months from now) | |
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
QOLIANA family patents